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Background: Colorectal cancer (CRC) is the most common cause of cancer death worldwide. Numerous studies
have identified the roles of survivin −31 G/C and angiotensin-converting enzyme insertion/deletion (ACE I/D)
polymorphisms in CRC risk; however, the results remain inconclusive. This study was to investigate associations
between these two polymorphisms and CRC susceptibility.
Methods: A comprehensive literature search was conducted to collect relevant case–control studies published
between 2000 and 2014. The extracted data were statistically analyzed, and the odds ratios (ORs) with 95%
confidence intervals (CIs) were employed to estimate the strength of association.
Results: A total of 11 studies were included in the meta-analysis. For survivin G/C polymorphism, six articles reported
1,840 cases and 1,804 controls. Overall, we found the frequency of C allele is higher in CRC cases than that in the
healthy controls (57.2% vs. 48.0%), and C allele significantly increased the risk of CRC compared to G allele in
allele model (OR = 1.46, 95% CI = 1.33–1.60, P < 0.00001). This association was also found in other genetic models
(P < 0.00001). Stratified analysis by ethnicity showed significant association in each genetic model among the
Asian population. For ACE I/D polymorphism, five studies included 758 cases and 6,755 controls. No significant
association was found in any genetic models.
Conclusions: Our results showed that survivin −31 G/C polymorphism might contribute to risk of CRC, especially
in the Asian populations. However, the ACE I/D polymorphism is not a genetic factor concerning the risk for CRC.
More studies with larger sample sizes are required in the future.
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Colorectal cancer (CRC) is one of the three most com-
mon cancers in the world and is a major contributor to
cancer-related death [1]. Each year, a global incidence
exceeding 1.2 million new cases emerge and 600,000
deaths occur [2]. Its incidence rates continue to increase
in economically transitioning countries. According to
colorectal cancer statistics, an estimated 71,830 men and
65,000 women will be diagnosed with CRC, and 26,270
men and 24,040 women will die of this disease in 2014
[3]. The etiological factors and pathogenetic mechanisms* Correspondence: caizhaolin_1@163.com
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unless otherwise stated.underlying CRC development appear to be complex and
heterogeneous. In the last two decades, studies have
demonstrated that CRC cells undergo major epigenetic
alterations [4]. Among which, genetic variants in onco-
genes have been extensively investigated as the essential
role in cancer etiology [5].
The survivin gene, located in chromosome 17q25, is
the smallest member of the inhibitor of apoptosis
(IAP) gene family [6]. It is a multifunctional protein
and is required to preserve tissue or organism viability
[7]. Survivin is expressed in many human cancers and
involved in the regulation of cell division and survival
[8]. The survivin −31 G/C polymorphism mayl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart of literature screening.
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expression of survivin. A recent study has supported a
role of survivin in colorectal carcinogenesis, while the
−31 G/C polymorphism may constitute a marker of
survival [9].
The angiotensin-converting enzyme (ACE), a major
component of the renin-angiotensin system (RAS), plays
a crucial role in the regulation of circulatory homeostasis
such as blood pressure and serum electrolytes [10]. It is
located on human chromosome 17q23 and has been in-
volved in the pathogenesis of human cancers [11,12].
Epidemiologic studies have indicated that inhibition ofTable 1 Main characteristic of the eligible studies
First author Year Country Ethnic
Survivin (−31 G/C)
Gazouli [16] 2009 Greece Caucas
Huang [17] 2010 China Asian
Antonacopoulou [9] 2011 Greece Caucas
Duan [18] 2012 China Asian
Liu [19] 2012 China Asian
Li [20] 2013 China Asian
ACE (I/D)
Nikiteas [21] 2007 Greece Caucas
Rocken [22] 2007 Germany Caucas
Van der [23] 2008 Netherlands Caucas
Toma [24] 2008 Romanian Caucas
Liu SY [25] 2011 China AsianACE activity could suppress tumor growth and angiogen-
esis, decreasing the risk and mortality rate [13]. Recent re-
search showed that long-term/high-dose exposure to ACE
inhibitor may decrease the incidence of CRC [14]. ACE
variants might affect its activity. Among which, ACE I/D
(rs4646994) polymorphism in intron 16 of this gene, based
on insertion (I) or deletion (D) of a 287-bp Alu sequence,
was the most widely studied and leaded to a change in the
plasma ACE level. The carriers of D allele were shown in
higher ACE activity.
Numerous studies have shown the association of these
genetic polymorphisms with CRC [9,15-25]. However,ity Cases Controls Genotyping method
ian 312 362 PCR-RFLP
702 711 PCR-RFLP




ian 92 102 PCR
ian 141 189 PCR
ian 176 6,015 PCR
ian 108 150 PCR
241 299 PCR-PAGE
Table 2 Distribution of genotypes in the individual studies
Cases Control
Survivin GG GC CC G C GG GC CC G C
Gazouli [16] 68 131 113 267 357 123 163 76 409 315
Huang [17] 144 302 256 590 814 180 345 186 705 717
Antonacopoulou [9] 63 84 16 210 116 66 50 16 182 82
Duan [18] 31 92 83 154 258 32 66 31 130 128
Liu [19] 36 76 70 148 216 54 93 53 201 199
Li [20] 42 123 110 207 343 55 138 77 248 292
ACE II ID DD I D II ID DD I D
Nikiteas [21] 15 27 50 57 127 6 44 52 56 148
Rocken [22] 37 69 35 143 139 41 95 53 177 201
Van derv [23] 34 97 45 165 187 1,332 3,006 1,677 5,670 6,360
Toma [24] 25 50 33 100 116 30 73 47 133 167
Liu SY [25] 71 138 32 280 202 95 158 46 348 250
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we performed meta-analyses to evaluate and summarize
the contribution of the two polymorphisms to CRC sus-
ceptibility in different populations.Methods
Literature search
A comprehensive literature search was conducted using
the online electronic database of Embase, Medline,
PubMed, CNKI (China National Knowledge Infrastruc-
ture), and Wanfang. We retrieved the relevant articles
published between January 2000 and March 2014 using
the following terms: “colorectal cancer or colorectal
carcinoma”, “angiotensin-converting enzyme or ACE”,
“survivin”, and “polymorphism or variant or mutation”
as well as their combinations. The references of re-
trieved articles were searched manually. When the
same authors or laboratory reported the issue on the
same group of people, only full-text articles of the most
recent studies were included.Study selection
The inclusion criteria were as follows: 1) case–control
or cohort studies, 2) evaluating the contribution ofTable 3 Meta-analysis of survivin −31 G/C polymorphism in C
Total Asian
OR (95% CI) P Ph OR (95% C
C vs. G 1.46 (1.33, 1.60) <0.00001 0.37/7% 1.42 (1.27, 1
CC vs. GG 1.95 (1.62, 2.35) <0.00001 0.25/25% 1.88 (1.52, 2
CC + GC vs. GG 1.51 (1.29, 1.76) <0.00001 0.67/0% 1.41 (1.17, 1
CC vs. GC + GG 1.72 (1.49, 1.99) <0.00001 0.23/28% 1.70 (1.44, 2survivin −31 G/C and ACE I/D polymorphisms with
CRC risk, 3) the results presented in odds ratio (OR)
with its 95% confidence interval (CI), and 4) genotype
distributions in the cases and controls were available to
extract.Data extraction
Two investigators independently assessed the data from
the included studies. Any disagreement was discussed
with a third expert to reach a final consensus. The fol-
lowing information was extracted: the name of first au-
thor, publication year, country, ethnicity, sample size,
genotyping method, and the genotype frequencies in the
cancer cases and controls.Statistical analysis
The overall effect was measured by ORs with its 95% CI.
The Z test was employed to determine the significance
of the pooled ORs, and a P value less than 0.05 was con-
sidered statistically significant. The per-allele model (C
vs. G for survivin, D vs. I for ACE), dominant model
(GC + CC vs. GG for survivin, ID + DD vs. II for ACE),
recessive model (CC vs. GC +GG survivin, DD vs. ID +
II for ACE), and additive model (CC vs. GG for survivin,RC by ethnicity analysis
Caucasian
I) P Ph OR (95% CI) P Ph
.58) <0.00001 0.64/0% 1.50 (1.07, 2.10) 0.02 0.09/64%
.33) <0.00001 0.62/0% 1.78 (0.71, 4.45) 0.22 0.04/77%
.70) 0.0003 0.72/0% 1.75 (1.33, 2.31) <0.0001 0.61/0%
.01) <0.00001 0.80/0% 1.37 (0.52, 3.62) 0.52 0.02/83%
Figure 2 Association between C allele of survivin −31 G/C polymorphism and CRC risk.
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ation. The I2 test and the Q statistic test were used to as-
sess the between-study heterogeneity. The Mantel-
Haenszel (M-H) fixed-effects model is used when the P
value is more than 0.10 for the Q test and less than 50%
for I2; otherwise, the random-effects model is used. The
publication bias was assessed by visual funnel plot in-
spection. Review Manager (version 5.2, The Cochrane
Collaboration) was used to conduct the statistical ana-
lyses. All the tests were two sided.
Results
Study selection and characteristics
The initial search identified 284 references. Of those,
107 records were excluded for duplication and 177 arti-
cles were judged potentially relevant. Following the title
and abstract screening, 40 full-text articles met inclusion
criteria. Overall, a total of 11 studies (eight in English
and three in Chinese) were finally included in this re-
view. Figure 1 showed the study flow.
Of the 11 case–control studies, there were five studies
of Asians and six of Caucasian. For ACE I/D polymorph-
ism, five studies containing 758 cases and 6,755 controls
were included. For survivin G/C polymorphism, six arti-
cles reported 1,840 cases and 1,804 controls. Table 1
summarized the main characteristics of included studies.
Table 2 showed the information of genotypes and alleles
for each case–control study.Figure 3 Forest plot of odd ratios (ORs) of survivin polymorphism (CCAssociation of survivin G/C polymorphism and CRC risk
Table 3 listed the results of allele and genotypes of survivin
polymorphism in this meta-analysis. The between-study
heterogeneity was not significant and the fixed-effect
model was employed. Overall, the frequency of C allele
was higher in CRC cases than that in the healthy controls
(57.2% vs. 48.0%). As shown in Figure 2, we found that
C allele significantly increased the risk of CRC com-
pared to G allele in the allele model (OR = 1.46, 95%
CI = 1.33–1.60, P < 0.00001). This significant associ-
ation was also found in other genetic models (CC vs.
GG: OR = 1.95, 95% CI = 1.62–2.35, P < 0.00001; CC +
GC vs. GG: OR = 1.51, 95% CI = 1.29–1.76, P < 0.00001;
CC vs. GC + GG: OR = 1.72, 95% CI = 1.49–1.99, P <
0.00001) as shown in Figures 3 and 4. When evaluating
the effect of the polymorphism by ethnicity, we found a
significant association in all genetic models among the
Asian population (C vs. G: OR = 1.42, 95% CI = 1.27–1.58,
P < 0.00001; CC vs. GG: OR = 1.88, 95% CI = 1.52–2.33,
P < 0.00001; CC + GC vs. GG: OR = 1.41, 95% CI =
1.17–1.70, P = 0.0003; CC vs. GC + GG: OR = 1.70, 95%
CI = 1.44–2.01, P < 0.00001) in a fixed-effect model.
Among the Caucasian population, Figure 5 showed that
C allele carrier was significantly associated with the
increased risk of CRC compared to healthy control
groups (CC + GC vs. GG: OR = 1.75, 95% CI = 1.33–
2.31, P < 0.0001). No relationship was found in other
genetic models (P > 0.05).vs. GG) associated with CRC risk.
Figure 4 Meta-analysis of survivin polymorphism (CC vs. GC + GG) with risk of CRC.
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Table 4 displayed the summary of all genetic compari-
sons between ACE I/D polymorphism and CRC risk.
The I2 was less than 50% and the P value was greater
than 0.01, suggesting no heterogeneity was present. As
shown in Figure 6, the result suggested that the variant
D allele did not have a significant increased risk of
CRC compared with those individuals without D allele
(D vs. I: OR = 0.96, 95% CI = 0.84–1.08, P = 0.48). No
significant association was found in other genetic models
(DD vs. II: OR = 0.86, 95% CI = 0.66–1.12, P = 0.25; DD +
ID vs. II: OR = 0.97, 95% CI = 0.79–1.19, P = 0.77; DD vs.
ID + II: OR = 0.91, 95% CI = 0.74–1.12, P = 0.39).
Sensitivity analysis and publication bias
A single study included in the meta-analysis was deleted
each time to reflect the influence of the individual data
set to the pooled ORs. The corresponding pooled ORs
were not materially changed, which confirmed the stabil-
ity of our overall result. The shape of funnel plots did
not reveal any evidence of funnel plot asymmetry
(Figure 7).Figure 5 Forest plot of CRC associated with distribution of survivin pDiscussion
CRC is a major cause of morbidity and mortality world-
wide. Although surgical resection remains a curative op-
tion for CRC treatment, most patients with CRC are not
suited for surgical operations because of the advanced
stage of the lesions when diagnosed. Thus, there is an
urgent need to identify newer biomarkers to evaluate the
severity of this disease, predict the prognosis of patients,
and target the pathogenic genes.
Recently, survivin has been reported to be overex-
pressed in almost all human tumors. It is considered as
a tumor-associated antigen for immune-based clinical
approaches in CRC [26]. Researchers have suggested
that survivin is implicated in the progression of dyspla-
sia to neoplasia in the colon [27]. A significant role of
survivin in CRC progression and recurrence of colon
cancer liver metastases has been previously demon-
strated [28]. The mechanisms of the survivin re-
expression in malignancies are still unclear due to the
complexity of its regulation. Genetic variations located
in the promoter of the survivin gene have impact on
the protein expression and consequently contributedolymorphism (CC + GC vs. GG) by stratified analysis.
Table 4 Meta-analysis of ACE I/D polymorphism in CRC
Genotype OR (95% CI) P Ph I2 (%) Model
D vs. I 0.96 (0.84, 1.08) 0.48 0.87 0 Fixed
DD vs. II 0.86 (0.66, 1.12) 0.25 0.48 0 Fixed
DD + ID vs. II 0.97 (0.79, 1.19) 0.77 0.12 46 Fixed
DD vs. ID + II 0.91 (0.74, 1.12) 0.39 0.93 0 Fixed
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polymorphism is the most extensively studied variant
located in the promoter region of survivin, and the C
allele has been identified to be associated with a
higher transcription activity of survivin [29]. This
meta-analysis showed that the survivin −31 G/C poly-
morphism was associated with increased CRC risk in
total populations as well as in Asians, while no associ-
ation was found in Caucasian except the dominant
model. Our result is in agreement with the study con-
ducted by Qin et al., which identified that this poly-
morphism is associated with elevated cancer risk [30].
Survivin acts as an antagonist of apoptotic cell death
and functions as a regulator of mitosis [31,32]. It is a
potentially interesting prognostic marker, implicating a
shift from adenoma with low dysplasia to high dysplasia
during human colorectal tumorigenesis [27]. Survivin
overexpression was related with the increase of invasion
and the metastasis of CRC [33]. A study conducted by
Choi et al. suggested that the nuclear expression of sur-
vivin might be associated with the metastasis of CRC to
the liver [34]. Survivin can be regulated by or cooperated
with other genes. The stimulation of survivin expression
by TCF/β catenin might contribute to the molecular
pathogenesis of CRC [35]. The positive expression of
survivin protein, directly correlated to that of Bcl-2,
acted on different stages of apoptosis to promote jointly
the development of CRC in a synergistic way [36]. The
combined expression levels of Aldh1, survivin, and
EpCAM as strong independent prognostic factors for
survival and tumor recurrence in colon cancer patients
reflect tumor aggressiveness [37]. Furthermore, survivin
is also a therapeutic target in cancers [38]. SurvivinFigure 6 Association between D allele of ACE I/D polymorphism andexpression increases during the normal mucosa-adenoma-
carcinoma sequence and is maintained throughout the
progression of disease, which strengthens its appeal as a
therapeutic target [39]. The expression of survivin may
play a role in identifying a subgroup of patients who
could benefit from a targeted therapy against survivin in
CRC [40].
Much evidence indicates that ACE associated with the
pathology of carcinomas. It is differentially expressed in
several malignancies. ACE is a monomeric glycoprotein
that is distributed in many tissues and biological fluids
[41]. ACE can influence tumor cell migration, prolifera-
tion, metastatic behavior, and angiogenesis [42]. The ex-
pression of ACE is upregulated in several cancers with
functions of angiogenesis and tumor cell growth [43].
Previous meta-analysis showed that the ACE I/D poly-
morphism is associated with hepatocellular carcinoma
(HCC), indicating that this polymorphism contributes to
HCC progression in the Chinese population [44]. Recent
analysis suggested that the ACE I/D polymorphism might
not be a common risk factor for overall cancer susceptibil-
ity [43]. Our results did not show any association between
ACE I/D polymorphism and CRC in each genetic models
(P > 0.05). This is in accordance with meta-analysis con-
ducted by Liu et al. and Zhang et al. [12,45].
Several limitations were presented in this meta-
analysis. Firstly, the number of included studies in the
subgroup analysis was small which may have a relatively
lower power. Secondly, other covariates such as age, sex,
and smoking condition should be considered if they are
available in each individual study to obtain a more pre-
cise result. Thirdly, the gene-gene interaction which is
important in developing complex diseases should also be
included.
Conclusions
In conclusion, the results from the present meta-analysis
suggest that the survivin −31 G/C polymorphism might
be correlated with an increased risk of CRC, indicating it
may serve as a biomarker of disease progression. How-
ever, ACE I/D polymorphism is not associated with CRC
risk. Further large and well-designed studies in variousCRC risk.
Figure 7 Begg’s funnel plot for publication bias in selection of studies (A for survivin, B for ACE).
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over, the studies of gene-gene and gene-environment in-
teractions between these polymorphisms and CRC risk
should also be performed and considered.
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